Currently-Recruiting Research Studies

If you are thinking about taking part in a research study, including a clinical trial, there’s a lot to consider. Check out our FAQs, as well as our lists of Ongoing Research Studies below and results from Past Research Studies. Please contact us at if you know of any additional studies or results, or if the recruitment status for a study has changed, etc… You may also be interested in our SomnusNooze articles about Research Studies.

Note: If you are interested in trying a clinical trial treatment that is not available in your country, a company like WEP Clinical may be able to help you access this treatment.

DISCLAIMER: This listing is provided merely for informational purposes. Listing a study on this site/web page does not mean that it has been independently evaluated by the Hypersomnia Foundation. The safety and scientific validity of a study listed here is the responsibility of the study sponsor and investigators, not the Hypersomnia Foundation. Before making any decision as to whether or not to participate in a particular research study, you should (1) know the risks and potential benefits of that research study, and (2) consult your own healthcare provider.


Hypersomnia Foundation CoRDS Patient Registry
The Hypersomnia Foundation’s International Registry at CoRDS

Have IH or a related disorder? Be sure to participate in (and keep updating) the Hypersomnia Foundation’s registry at CoRDS (Coordination of Rare Diseases at Sanford). NOW RECRUITING people with IH and all related disorders INTERNATIONALLY! CLICK HERE for more information and to enroll or update. CoRDS is also listed at ClinicalTrials.gov.

And check out some initial results from the registry:


Pregnancy and Medication Registries

NOW RECRUITING pregnant women. If you are taking (or plan to take) any medication while pregnant, we strongly encourage you to participate in Pregnancy Registries to help further knowledge about medication safety during pregnancy. You can find a list of these Pregnancy Registries in the U.S. HERE. For pregnancy registries in other countries, ask your doctor(s) to direct you (and then please share this information with the HF at ).


A Pharmacokinetic and Safety Study of TAK-925 (an orexin 2 receptor agonist) in Participants with IH (Sparkle 2002) and Narcolepsy (Sparkle 1501)

The SPARKLE studies are testing an investigational drug (TAK-925, an orexin 2 receptor agonist) to see if it could potentially be a safe and effective way to help increase wakefulness for people with idiopathic hypersomnia or narcolepsy. A study doctor and staff can explain to you in greater detail other requirements and eligibility criteria you would have to meet to participate in the study. The total amount of time you may be involved in the study is up to 43 days. You will be reimbursed for your time and travel.

SPARKLE 2002: NOW RECRUITING in the U.S., adults age 18-75 with IH (who first experienced symptoms between age 10-30): CLICK HERE to see if you qualify. For further info from ClinicalTrials.gov, CLICK HERE.

SPARKLE 1501: NOW RECRUITING in the U.S., adults age 18-65 with narcolepsy (with or without cataplexy): CLICK HERE to see if you qualify. For further info from ClinicalTrials.gov, CLICK HERE.

This is a follow-up to Takeda's earlier studies: 1) "Phase 1 TAK-925 Study in Healthy Adult and Elderly Volunteers and Patients with Narcolepsy" (CLICK HERE to read more); 2) "A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TAK-925 in Healthy Volunteers and Patients with Narcolepsy" (CLICK HERE to read more).


A Study of the Efficacy and Safety of JZP-258 in the Treatment of IH

Jazz Pharmaceuticals’ trial of JZP-258 (a low-sodium alternative for Xyrem): CLICK HERENOW RECRUITING adults age 18-75 with IH across the USA and Europe (over 40 study locations including Belgium, Czechia, Finland, Poland, and Spain). Similar study of the Efficacy and Safety of JZP-258 in Subjects with Narcolepsy with Cataplexy: CLICK HERE (recruitment complete).

In July 2020, Jazz Pharmaceuticals announced the U.S. FDA's approval of Xywav (JZP-258), as a treatment for cataplexy or excessive daytime sleepiness in narcolepsy patients.

Clinical trials for IH are ongoing despite COVID-19, with a target completion date of September 2020. Read more here.


Pathophysiology of Narcolepsy and Idiopathic Hypersomnia: a Multimodal Neuroimaging Study

NOW RECRUITING people with IH and narcolepsy (no geographical restriction, but if participants come from another time zone, they will require some adaptation to the study time zone prior to beginning the study). The project is to investigate brain regions underlying narcolepsy (with or without cataplexy) and idiopathic hypersomnia. The study includes an MRI scan session and two (non-consecutive) overnight sleep sessions at the sleep laboratory at the Institut Universitaire de Gériatrie de Montréal Research Center on Queen Mar Road in Montreal, Canada. Inclusion criteria are (1) Diagnosis of idiopathic hypersomnia or narcolepsy with or without cataplexy; (2) Age of 18 or more. Exclusion criteria are (1) Other sleep disorders; (2) Neurological disorders or head trauma; (3) Psychiatric disorders or use of psychotropic drugs; (4) Pregnancy or breastfeeding; (5) Pacemaker or metallic prosthesis. Participants will receive Can$200 of compensation if they complete the full study. For travel costs (if required, for those from other provinces or countries), up to Can$150 in travel reimbursements can be provided. If interested, please contact Elizaveta Frolova, Research Coordinator, via email: .


Pediatric Hypersomnia Screening Survey

NOW RECRUITING children with IH, narcolepsy, other sleep disorders, or normal healthy sleep in the U.S. Dr. Kiran Maski, pediatric neurologist and sleep medicine specialist at Boston Children’s Hospital, and a member of the Hypersomnia Foundation’s Medical Advisory Board, has developed a questionnaire that aims to improve screening for narcolepsy and idiopathic hypersomnia, with the goal of helping health care professionals identify hypersomnia symptoms quickly. Boston Children’s Hospital is looking for participants between the ages of 8-18 years who have been recently diagnosed (within 1 year) with narcolepsy or idiopathic hypersomnia (or who are awaiting diagnosis with sleep study testing) to answer an online questionnaire, which should take no more than 10-15 minutes. They are also looking for children to take the survey as a clinical control group, who 1) are healthy, medication free, and without sleep problems or 2) have any other type of diagnosed sleep disorder (insomnia, sleep apnea, restless leg, delayed sleep phase, etc.). As a token of appreciation, the researchers will provide a $10 gift card if you qualify and complete the survey. If you would like to learn more about the study or are interested in participating, please send an email to Neuro Sleep Research () or call 617-919-6212. More info HERE.


Clarithromycin Mechanisms in Hypersomnia Syndromes

NOW RECRUITING adults age 18-45 with IH and narcolepsy type 2 at Emory University in Atlanta, GA, U.S.: CLICK HERE. “The purpose of this study is to evaluate a medication called clarithromycin for treating sleepiness in two related conditions, narcolepsy without cataplexy and idiopathic hypersomnia. Studies have shown that clarithromycin can reduce sleepiness, but researchers do not know how clarithromycin does this. This study will look at brain activity (on magnetic resonance imaging [MRI] and electroencephalogram [EEG] brainwaves), inflammation, bacteria living in the gut, and cerebrospinal fluid, to better understand how clarithromycin can reduce sleepiness. This study will recruit 92 participants who will be randomized to receive clarithromycin or a placebo for 14 days.”


Modafinil Versus Amphetamines for the Treatment of Narcolepsy Type 2 and Idiopathic Hypersomnia

NOW RECRUITING adults with IH or NT2 (who are newly diagnosed and untreated) at Emory University in Atlanta, GA, U.S.: CLICK HERE. “This study will evaluate which medication works better to improve sleepiness. The researchers will also see which medication is better for other symptoms including difficulty waking up and difficulty thinking, as well as seeing which medication causes fewer side [effects]. Finally, this study will see if any information about patients (such as age or sleep study features) predicts responding better to one medication or the other.”


Transcranial Direct Current (tDCS) Stimulation Therapy for Central Hypersomnia Without Cataplexy

NOW RECRUITING adults age 18-70 with IH and narcolepsy type 2 at The Ohio State University: CLICK HERE. See also: A Pilot Study of tDCS Looks Promising for the Treatment of Idiopathic Hypersomnia.


Sodium Oxybate (Xyrem) for Treatment of Excessive Daytime Sleepiness due to IH

NOW RECRUITING adults age 18-60 with IH in FRANCE: CLICK HERE. This study, sponsored by the University Hospital in Montpellier, France, will evaluate the efficacy of sodium oxybate (marketed as Xyrem) on excessive daytime sleepiness in people with idiopathic hypersomnia.


Constitution of a Clinical, Neurophysiological and Biological Cohort for Chronic Sleep Disorders Responsible of Hypersomnolence (Somnobank)

NOW RECRUITING people with hypersomnias in France: CLICK HERE. University Hospital in Montpellier, France is looking for volunteers age 8 and older suffering from chronic sleep disorders. The creation of a Clinical, Neurophysiological and Biological Cohort will focus on collecting data on severity of symptoms and genetic testing of blood samples to better understand the pathophysiology of hypersomnolence. While cohorts of this type have aided the understanding of narcolepsy type 1, the pathophysiology of narcolepsy type 2 (NT2), idiopathic hypersomnia (IH) and Kleine-Levin syndrome (KLS) is still unknown, due to the small number of patients studied. The study is recruiting volunteers according to the following ratio: NT1 (33%), other central hypersomnias (NT2, IH, KLS, 33%), and hypersomnolence secondary to a neurological sleep or vigilance disorder (ADHD, RLS, parasomnias, 33%).


The Role of the Circadian System in Neurological Sleep-Wake Disorders

NOW RECRUITING adults age 18-35 with IH or narcolepsy type 1 (or who are healthy) at University Hospital Zurich: CLICK HERE.


Newcastle, NSW, Australia Study of Alternative Therapies in Hypersomnia

NOW RECRUITING adults with IH in Australia. The Adult Sleep Laboratory in Newcastle, NSW, Australia, is looking for adult volunteers for a research study investigating the effectiveness of alternative therapies on sleep and daytime alertness in adults aged 18 years or older with a diagnosis of hypersomnia. Visit the Sleep Health Foundation website for more information and to see if you qualify.


Validation of Non-Invasive Miniature Optical Sensors for Scoring Sleep Stages

NOW RECRUITING healthy adults and those with sleep wake disorders in Switzerland at University Hospital Bern: CLICK HERE.


Evaluation of the Efficacy of Sodium Oxybate (Xyrem) in Treatment of Post-traumatic Narcolepsy and Post-traumatic Hypersomnia

NOW RECRUITING adults with post-traumatic hypersomnias at Brigham and Women’s Hospital in Boston, MA, U.S.: CLICK HERE.


Hypersomnia in Major Depressive Disorder

NOW RECRUITING adults age 18-64 with major depression (with or without hypersomnolence) at The Chinese University of Hong Kong: CLICK HERE.


Importance of Sleep Deprivation in Differential Diagnosis of Primary Hypersomnia

RECRUITMENT STATUS UNKNOWN – Was recruiting adults in France with a sleepiness evoking a primary hypersomnia (not yet diagnosed with a hypersomnia): CLICK HERE.


Additional Research Studies

CLICK HERE for additional research studies, including those for related disorders, from ClinicalTrials.gov and similar international public clinical trials registries.